VFA
FOLD

Virtus Fund Advisers’s Amicus Therapeutics FOLD Stock Holding History

Virtus Fund Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$29.3K Buy
+3,108
New +$32.3K 0.09% 94
2017
Q4 		$392K Buy
+27,241
New +$374K ﹤0.01% 359

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Virtus Fund Advisers's FOLD Position: Q4 2024 in Review

Virtus Fund Advisers opened a new position in Amicus Therapeutics (FOLD) in Q4 2024: 3,108 shares worth $29.3K. The stake represents 0.09% of the portfolio and ranks #94 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in FOLD as recently as Q4 2017.

Virtus Fund Advisers first reported a position in FOLD in Q4 2017 and has held it in 2 quarters since. The position peaked at $392K in Q4 2017. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • Virtus Fund Advisers held 3,108 shares of Amicus Therapeutics worth $29.3K as of Q4 2024.
  • Amicus Therapeutics was a new Virtus Fund Advisers position in Q4 2024.
  • Amicus Therapeutics made up 0.09% of Virtus Fund Advisers's portfolio in Q4 2024, its #94 holding.
  • Virtus Fund Advisers first reported a position in Amicus Therapeutics in Q4 2017 and has held it in 2 quarters since.
  • Virtus Fund Advisers's Amicus Therapeutics position peaked at $392K in Q4 2017.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.